1. Home
  2. |Insights
  3. |Litigation Note: Crowell & Moring Secures IP Victory for Watson Pharmaceuticals (now Actavis)

Litigation Note: Crowell & Moring Secures IP Victory for Watson Pharmaceuticals (now Actavis)

Firm News | less than 1 min read | 04.15.13

Washington, D.C. – April 15, 2013: Crowell & Moring represented Watson Pharmaceuticals, Inc. (now Actavis, Inc.) in successfully defending the patent infringement case brought by Bayer HealthCare Pharmaceuticals Inc. regarding its RE37,564 patent for the Yaz ® contraceptive. Today, the Federal Circuit reversed the adverse summary judgment decision made by the district court in March 2012 and held that Bayer's asserted patent claims were invalid. The court found that the cited prior art references set forth every limitation required by the asserted claims and provide express motivation to combine those teachings to derive the claimed oral contraceptive product. As a result of the decision today, Actavis has re-launched its generic product.


Insights

Firm News | 2 min read | 05.20.26

Crowell Secures $23.3 Million Jury Verdict for C3.ai in Major Trade Secret Case

Washington – May 20, 2026: Crowell & Moring achieved a decisive victory for leading Enterprise AI application software company C3.ai, obtaining a $23.3 million jury verdict following a seven-day trial in Wilmington, Delaware. The jury unanimously found Cummins liable for trade secret misappropriation and breach of contract in a suit brought by C3.ai more than two and a half years ago....